AACR Annual Meeting | Conference

Dr. Hodi on Nivolumab in Combination With Ipilimumab for Advanced Melanoma

April 20th 2015

F. Stephen Hodi, MD, discusses the results of a trial presented at the 2015 AACR Annual Meeting.

Anti-PD-L1 Agent MPDL3280A Shows Durable Responses in TNBC

April 20th 2015

The PD-L1 inhibitor MPDL3280A demonstrated a 19% objective response rate (ORR) with 75% of responses ongoing in pretreated patients with metastatic triple-negative breast cancer.

Long-term Aspirin Use Decreases Risk of GI Cancers, Especially Colorectal

April 20th 2015

A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.

Dr. Evan Alley on KEYNOTE-028 Trial Results in Mesothelioma

April 20th 2015

Evan W. Alley, MD, PhD, discusses the results from the phase Ib KEYNOTE-028 trial on a cohort of patients with malignant pleural mesothelioma.

MM-302 Shows Clinical Activity, Tolerability in Heavily-Pretreated HER2+ Breast Cancer

April 20th 2015

MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.

Pembrolizumab Nears 50% Response in High PD-L1-Expressing NSCLC

April 19th 2015

Pembrolizumab had an overall response rate (ORR) of 45.2% among a cohort of patients with PD-L1-positive non–small cell lung cancer (NSCLC) and an ORR of nearly 20% in the full population in the phase I KEYNOTE-001 trial.

Breakthrough T-Cell Therapy Halts EBV-Associated Lymphoproliferative Disorders

April 19th 2015

Infusions of Epstein-Barr virus (EBV)–specific cytotoxic T lymphocytes from healthy donors led to high response rates and significant extensions in overall survival for patients with rituximab-refractory EBV–associated lymphoproliferative disorders.

Frontline Pembrolizumab Trumps Ipilimumab in Head-to-Head Melanoma Trial

April 19th 2015

Pembrolizumab elicited significantly better outcomes compared with ipilimumab in a randomized phase III trial of patients with advanced melanoma.

Dr. Heymach on New KRAS Subsets in Lung Cancer

April 19th 2015

John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses a study on KRAS mutations in lung cancer, which led to the identification of three more KRAS subsets.

Bispecific Immunotherapy Elicits Intriguing Responses in Melanoma

April 19th 2015

IMCgp100 yielded long-lasting responses in patients with advanced melanoma, according to results from a 17-patient expansion cohort presented at the 2015 AACR Annual Meeting.

Irregular Menstruation Linked to Higher Risk of Ovarian Cancer Death

April 9th 2014

A prospective study found that women with irregular menstrual cycles have a 2.4-fold increased risk of dying from ovarian cancer compared to women with normal menstrual cycles

Dr. Schenkein on AG-221 for the Treatment of AML

April 8th 2014

David Schenkein, MD, Chief Executive Officer, Agios Pharmaceuticals, discusses AG-221 for the treatment of acute myeloid leukemia (AML).

PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC

April 7th 2014

PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma

Dr. Flynn on CDK Inhibitors for the Treatment of CLL

April 7th 2014

Joseph M. Flynn, DO, MPH, FACP, co-director, Division of Hematology, associate physician-in-chief, OSUCCC - James, discusses cyclin-dependent kinase (CDK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL).

David Lucas Discusses the Bromodomain Inhibitor OTX015

April 7th 2014

David Lucas, PhD, assistant professor, division of hematology, Ohio State University, discusses the bromodomain inhibitor OTX015.

I-SPY 2 Trial Graduates Neratinib for HER2-Positive Breast Cancer

April 7th 2014

The adaptive I-SPY 2 trial has found that a neoadjuvant regimen of neratinib and standard chemotherapy is beneficial for high-risk patients with hormone receptor (HR)-negative, HER2-positive stage II/III breast cancer

Palbociclib Dramatically Improves PFS in Updated Phase II Findings

April 7th 2014

The combination of palbociclib and letrozole more than doubled PFS and showed a non–statistically significant 4.2-month improvement in OS for patients with ER-positive, HER2-negative metastatic breast cancer.

CDK4/6 Inhibitor LY2835219 Shows Promise in Early Study

April 7th 2014

The CDK4/6 inhibitor LY2835219 demonstrated promising single-agent activity in heavily pretreated patients with HR-positive metastatic breast cancer.

NEXT PAGE
PREVIOUS PAGE
x